PMID- 22098724
OWN - NLM
STAT- MEDLINE
DCOM- 20140409
LR  - 20211203
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
VI  - 78
IP  - 2
DP  - 2012 Feb
TI  - Adriamycin induced spermatogenesis defect is due to the reduction in epididymal 
      adipose tissue mass: a possible hypothesis.
PG  - 218-20
LID - 10.1016/j.mehy.2011.10.027 [doi]
AB  - Adriamycin is an anthracycline antibiotic used as anticancer drug since past few 
      decades. Though effective against cancer, it is cardiotoxic, nephrotoxic, 
      hepatotoxic and also toxic for reproductive system. Although a number of 
      potential toxic mechanisms have been identified following exposure to adriamycin, 
      the major pathogenic mechanism appears to be the generation of toxic reactive 
      oxygen species (ROS). Animals treated with adriamycin have shown a decrease in 
      total sperm count. This implies that adriamycin impairs the process of 
      spermatogenesis. Epididymal white adipose tissue (EWAT) is necessary for normal 
      spermatogenesis, and decrease in the EWAT causes disturbance in spermatogenesis. 
      Factor X is an unknown molecule synthesized by EWAT that plays crucial role in 
      spermatogenesis. Adriamycin inhibits Kruppel-like factor 4 (KLF-4) and thus 
      downregulates the adipogenesis process needed to maintain the EWAT mass. Apart 
      form adipocytes, KLF-4 and peroxisome proliferator-activated receptor gamma 
      (PPAR-gamma) are also found in spermatogonium and testis, implying its vital role in 
      spermatogenesis. Adriamycin treatment inhibits KLF-4 and thus PPAR-gamma in EWAT and 
      spermatogonium. Reduction of EWAT might cause a decrease in Factor X level. 
      Declining of Factor X level, KLF-4 and PPAR-gamma together will lead to disturbance 
      in spermatogenesis process.
CI  - Copyright (c) 2011 Elsevier Ltd. All rights reserved.
FAU - Pichiah, P B Tirupathi
AU  - Pichiah PB
AD  - Department of Food Science & Human Nutrition, Chonbuk National University, 664-14 
      Duckjin-dong, Jeonju, Jeonbuk 561-756, Republic of Korea.
FAU - Sankarganesh, A
AU  - Sankarganesh A
FAU - Kalaiselvi, S
AU  - Kalaiselvi S
FAU - Indirani, K
AU  - Indirani K
FAU - Kamalakkannan, S
AU  - Kamalakkannan S
FAU - SankarGanesh, D
AU  - SankarGanesh D
FAU - Hwang, Pyoung-Han
AU  - Hwang PH
FAU - Cha, Youn Soo
AU  - Cha YS
FAU - Achiraman, S
AU  - Achiraman S
LA  - eng
PT  - Journal Article
DEP - 20111117
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (KLF4 protein, human)
RN  - 0 (Kruppel-Like Factor 4)
RN  - 0 (Kruppel-Like Transcription Factors)
RN  - 0 (PPAR gamma)
RN  - 0 (Reactive Oxygen Species)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Adipose Tissue/*drug effects
MH  - Adipose Tissue, White/drug effects
MH  - Animals
MH  - Antibiotics, Antineoplastic/*adverse effects
MH  - Doxorubicin/*adverse effects
MH  - Epididymis/*drug effects
MH  - Humans
MH  - Kruppel-Like Factor 4
MH  - Kruppel-Like Transcription Factors/metabolism
MH  - Male
MH  - PPAR gamma/metabolism
MH  - Reactive Oxygen Species
MH  - Sperm Count
MH  - Spermatogenesis/*drug effects
EDAT- 2011/11/22 06:00
MHDA- 2014/04/10 06:00
CRDT- 2011/11/22 06:00
PHST- 2011/08/13 00:00 [received]
PHST- 2011/10/23 00:00 [accepted]
PHST- 2011/11/22 06:00 [entrez]
PHST- 2011/11/22 06:00 [pubmed]
PHST- 2014/04/10 06:00 [medline]
AID - S0306-9877(11)00554-8 [pii]
AID - 10.1016/j.mehy.2011.10.027 [doi]
PST - ppublish
SO  - Med Hypotheses. 2012 Feb;78(2):218-20. doi: 10.1016/j.mehy.2011.10.027. Epub 2011 
      Nov 17.